Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928472 · ClinicalTrials.gov registry record · Phase 1
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
A Phase 1 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 1
- Development phase
- 402
- Enrollment target
NCT01928472: Completed Phase 1 study, sponsored by Novartis Vaccines.
NCT01928472 is a Phase 1 study that has completed, run by Novartis Vaccines. The registered enrollment target is 402 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (570% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01928472, a Phase 1 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 402 participants
- Enrollment target
Study Summary
Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
Primary Outcome
Immunogenicity was measured by Hemagglutination Inhibition (HI) assay and summarized through the geometric mean titers (GMTs) at baseline (day 1) and three weeks after the second (day 43) vaccination
Interventions
- BIOLOGICAL H7N9c low dose with adjuvant
- BIOLOGICAL H7N9c medium dose with adjuvant
- BIOLOGICAL H7N9c high dose with adjuvant
- BIOLOGICAL H7N9c high dose without adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
What the finished NCT01928472 record still lists
NCT01928472 is an interventional study that assigns participants to a tested intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (570% higher).
The record links to 0 conditions, and to 4 interventions - of which H7N9c low dose with adjuvant is the first listed.
NCT01928472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01928472 about?
NCT01928472 is a clinical study titled "Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years". Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
What is the current status of trial NCT01928472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 402 participants. The study started on 2013-08. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01928472?
The interventions under investigation include: H7N9c low dose with adjuvant (BIOLOGICAL), H7N9c medium dose with adjuvant (BIOLOGICAL), H7N9c high dose with adjuvant (BIOLOGICAL), H7N9c high dose without adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01928472?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01928472's enrollment target sits among peer trials
402 75th of 2000 higher than 1,926 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia